A. F. Francisco

This study establishes a hamster model of Trypanosoma cruzi infection using bioluminescence imaging, revealing chronic tissue pathology and motor dysfunction not seen in mice.

This study identifies benznidazole-treated Trypanosoma cruzi persisters as transient non-proliferative parasites, not localized to specific tissues, and suggests their survival may involve DNA damage response or pre-existing non-replicative states.

This study shows that curative treatment with benznidazole at 6 weeks post-infection reverses digestive Chagas disease symptoms in mice, while delayed treatment leads to irreversible damage.

This paper evaluates nitroimidazopyrazinone derivatives for antitubercular and antiparasitic activity, showing selectivity against M. tuberculosis and efficacy against T. cruzi in mouse models.

This study identifies skeletal muscle and skin as major sites of Trypanosoma cruzi persistence in chronic murine infections using high-sensitivity imaging.

This study uses genetically modified parasites to show that T. cruzi replication and differentiation are asynchronous within host cells throughout infection.

This study shows that drug-cured Trypanosoma cruzi infections in mice provide long-lasting, cross-strain immunity against re-infection, outperforming recombinant vaccines.

This paper demonstrates that a single dose of an antibody-drug conjugate targeting the trypanosome receptor HpHbR completely cures a stage 1 mouse model of African trypanosomiasis.